FR2934266B1 - Derives azotes de la pancratistatine - Google Patents

Derives azotes de la pancratistatine

Info

Publication number
FR2934266B1
FR2934266B1 FR0855161A FR0855161A FR2934266B1 FR 2934266 B1 FR2934266 B1 FR 2934266B1 FR 0855161 A FR0855161 A FR 0855161A FR 0855161 A FR0855161 A FR 0855161A FR 2934266 B1 FR2934266 B1 FR 2934266B1
Authority
FR
France
Prior art keywords
pancratistatin
nitrogen derivatives
derivatives
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0855161A
Other languages
English (en)
Other versions
FR2934266A1 (fr
Inventor
Frederic Marion
Jean Philippe Annereau
Jacques Fahy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40394438&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2934266(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR0855161A priority Critical patent/FR2934266B1/fr
Priority to TW098125189A priority patent/TW201011031A/zh
Priority to GEAP200912118A priority patent/GEP20135818B/en
Priority to HUE09781165A priority patent/HUE028098T2/en
Priority to EP09781165.7A priority patent/EP2324031B1/fr
Priority to PCT/EP2009/059715 priority patent/WO2010012714A1/fr
Priority to US13/055,947 priority patent/US8415348B2/en
Priority to JP2011520466A priority patent/JP5666442B2/ja
Priority to ARP090102865A priority patent/AR072880A1/es
Priority to CN2009801342179A priority patent/CN102137867A/zh
Priority to BRPI0916716A priority patent/BRPI0916716A2/pt
Priority to CA2731901A priority patent/CA2731901A1/fr
Priority to MX2011000956A priority patent/MX2011000956A/es
Priority to ES09781165.7T priority patent/ES2584165T3/es
Priority to RU2011106570/04A priority patent/RU2011106570A/ru
Priority to KR1020117004221A priority patent/KR20110036842A/ko
Priority to AU2009275929A priority patent/AU2009275929B2/en
Priority to PL09781165.7T priority patent/PL2324031T3/pl
Priority to NZ591298A priority patent/NZ591298A/en
Publication of FR2934266A1 publication Critical patent/FR2934266A1/fr
Publication of FR2934266B1 publication Critical patent/FR2934266B1/fr
Application granted granted Critical
Priority to IL210868A priority patent/IL210868A0/en
Priority to CL2011000168A priority patent/CL2011000168A1/es
Priority to ZA2011/01426A priority patent/ZA201101426B/en
Priority to CO11023614A priority patent/CO6341557A2/es
Priority to MA33648A priority patent/MA32588B1/fr
Priority to US13/727,101 priority patent/US8697064B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR0855161A 2008-07-28 2008-07-28 Derives azotes de la pancratistatine Active FR2934266B1 (fr)

Priority Applications (25)

Application Number Priority Date Filing Date Title
FR0855161A FR2934266B1 (fr) 2008-07-28 2008-07-28 Derives azotes de la pancratistatine
TW098125189A TW201011031A (en) 2008-07-28 2009-07-27 Nitrogenated derivatives of pancratistatin
RU2011106570/04A RU2011106570A (ru) 2008-07-28 2009-07-28 Азотсодержащие производные панкратистатина
KR1020117004221A KR20110036842A (ko) 2008-07-28 2009-07-28 판크라티스타틴의 질소화된 유도체
EP09781165.7A EP2324031B1 (fr) 2008-07-28 2009-07-28 Dérivés azotés de pancratistatine
PCT/EP2009/059715 WO2010012714A1 (fr) 2008-07-28 2009-07-28 Dérivés azotés de pancratistatine
US13/055,947 US8415348B2 (en) 2008-07-28 2009-07-28 Nitrogenated derivatives of pancratistatin
JP2011520466A JP5666442B2 (ja) 2008-07-28 2009-07-28 パンクラチスタチンの窒素化誘導体
ARP090102865A AR072880A1 (es) 2008-07-28 2009-07-28 Derivados nitrogenados de la pancratistatina
CN2009801342179A CN102137867A (zh) 2008-07-28 2009-07-28 水鬼蕉碱的氮化衍生物
BRPI0916716A BRPI0916716A2 (pt) 2008-07-28 2009-07-28 derivados nitrogenados de pancratistatin
CA2731901A CA2731901A1 (fr) 2008-07-28 2009-07-28 Derives azotes de pancratistatine
MX2011000956A MX2011000956A (es) 2008-07-28 2009-07-28 Derivados nitrogenados de la pancratistatina.
ES09781165.7T ES2584165T3 (es) 2008-07-28 2009-07-28 Derivados nitrogenados de la pancratistatina
GEAP200912118A GEP20135818B (en) 2008-07-28 2009-07-28 Nitrogenated derivatives of pancratistatin
HUE09781165A HUE028098T2 (en) 2008-07-28 2009-07-28 Nitrogenated derivatives of pancratostatin
AU2009275929A AU2009275929B2 (en) 2008-07-28 2009-07-28 Nitrogenated derivatives of pancratistatin
PL09781165.7T PL2324031T3 (pl) 2008-07-28 2009-07-28 Pochodne azotowe pankratystatyny
NZ591298A NZ591298A (en) 2008-07-28 2009-07-28 Nitrogenated derivatives of pancratistatin
IL210868A IL210868A0 (en) 2008-07-28 2011-01-25 Nitrogenated derivatives of pancratistatin
CL2011000168A CL2011000168A1 (es) 2008-07-28 2011-01-27 Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
ZA2011/01426A ZA201101426B (en) 2008-07-28 2011-02-23 Nitrogenated derivatives of pancratistatin
CO11023614A CO6341557A2 (es) 2008-07-28 2011-02-25 Derivados nitrogenados de la pancratistatina
MA33648A MA32588B1 (fr) 2008-07-28 2011-02-28 Derives azotes de la pancratistatine
US13/727,101 US8697064B2 (en) 2008-07-28 2012-12-26 Nitrogenated derivatives of pancratistatin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0855161A FR2934266B1 (fr) 2008-07-28 2008-07-28 Derives azotes de la pancratistatine

Publications (2)

Publication Number Publication Date
FR2934266A1 FR2934266A1 (fr) 2010-01-29
FR2934266B1 true FR2934266B1 (fr) 2010-09-17

Family

ID=40394438

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0855161A Active FR2934266B1 (fr) 2008-07-28 2008-07-28 Derives azotes de la pancratistatine

Country Status (24)

Country Link
US (2) US8415348B2 (fr)
EP (1) EP2324031B1 (fr)
JP (1) JP5666442B2 (fr)
KR (1) KR20110036842A (fr)
CN (1) CN102137867A (fr)
AR (1) AR072880A1 (fr)
AU (1) AU2009275929B2 (fr)
BR (1) BRPI0916716A2 (fr)
CA (1) CA2731901A1 (fr)
CL (1) CL2011000168A1 (fr)
CO (1) CO6341557A2 (fr)
ES (1) ES2584165T3 (fr)
FR (1) FR2934266B1 (fr)
GE (1) GEP20135818B (fr)
HU (1) HUE028098T2 (fr)
IL (1) IL210868A0 (fr)
MA (1) MA32588B1 (fr)
MX (1) MX2011000956A (fr)
NZ (1) NZ591298A (fr)
PL (1) PL2324031T3 (fr)
RU (1) RU2011106570A (fr)
TW (1) TW201011031A (fr)
WO (1) WO2010012714A1 (fr)
ZA (1) ZA201101426B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2747565A1 (fr) * 2008-12-18 2010-06-24 Brock University Nouveaux analogues substitues en c-1 de la pancratistatine et de la 7-desoxypancratistatine et leurs procedes de preparation
CN101805384B (zh) * 2010-04-26 2014-08-20 江苏省中国科学院植物研究所 一种新石蒜异喹诺酮类生物碱及其制备方法和用途
GB2498539A (en) * 2012-01-18 2013-07-24 Renesas Mobile Corp Base station assisted asymmetric device-to-device communications
CN106543194A (zh) * 2015-09-22 2017-03-29 孙青* 水仙环素衍生物及其制备与在制备抗肿瘤药物中的应用
CN105481880B (zh) * 2015-12-01 2017-07-14 哈尔滨凝昇科技有限公司 一种新化合物及其应用
CN115677714A (zh) * 2022-11-01 2023-02-03 昆明医科大学 (+)-水鬼蕉碱制备中的中间体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985436A (en) * 1984-02-17 1991-01-15 Arizona Board Of Regents Composition of matter for inhibiting leukemias and sarcomas
US5529989A (en) * 1995-01-09 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Pancratistatin prodrug
WO2004052298A2 (fr) * 2002-12-09 2004-06-24 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Promedicaments a base de narcistatine
EP1644001A4 (fr) * 2003-06-20 2010-01-20 Arizona Board Regents A Body C Promedicaments de phosphate cyclique de pancratistatine et promedicaments de phosphate cyclique de phenpanstatine
US20050261246A1 (en) 2004-03-05 2005-11-24 The Arizona Board Of Regents Methods for treating inflammatory and autoimmune diseases
CA2594569A1 (fr) * 2005-01-14 2006-07-20 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Actin G For And On Behalf Of Arizona State University Synthese de narcistatine de sodium et composes associes
US20100076005A1 (en) * 2006-10-13 2010-03-25 Unibioscreen Sa Isocarbostyril alkaloid derivatives having anti-proliferative and anti-migratory activities
CA2747565A1 (fr) * 2008-12-18 2010-06-24 Brock University Nouveaux analogues substitues en c-1 de la pancratistatine et de la 7-desoxypancratistatine et leurs procedes de preparation

Also Published As

Publication number Publication date
WO2010012714A1 (fr) 2010-02-04
RU2011106570A (ru) 2012-09-10
AU2009275929B2 (en) 2013-06-20
EP2324031A1 (fr) 2011-05-25
US20110123516A1 (en) 2011-05-26
CL2011000168A1 (es) 2011-07-15
JP5666442B2 (ja) 2015-02-12
NZ591298A (en) 2011-12-22
PL2324031T3 (pl) 2016-11-30
ES2584165T3 (es) 2016-09-26
ZA201101426B (en) 2011-10-26
TW201011031A (en) 2010-03-16
KR20110036842A (ko) 2011-04-11
HUE028098T2 (en) 2016-11-28
FR2934266A1 (fr) 2010-01-29
EP2324031B1 (fr) 2016-05-04
AR072880A1 (es) 2010-09-29
BRPI0916716A2 (pt) 2015-11-10
IL210868A0 (en) 2011-04-28
AU2009275929A1 (en) 2010-02-04
US8697064B2 (en) 2014-04-15
CO6341557A2 (es) 2011-11-21
MA32588B1 (fr) 2011-08-01
GEP20135818B (en) 2013-05-10
JP2011529097A (ja) 2011-12-01
CN102137867A (zh) 2011-07-27
US20130121986A1 (en) 2013-05-16
CA2731901A1 (fr) 2010-02-04
US8415348B2 (en) 2013-04-09
MX2011000956A (es) 2011-07-29

Similar Documents

Publication Publication Date Title
NL300938I2 (nl) Niraparib tosylaat of niraparib tosylaat monohydraat
CY2019027I2 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
SMT201600198B (it) Derivati di 1,2,4-triazina-4-ammina
BRPI0906598A2 (pt) Oxim derivattivos como inibidores hsp90
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
BRPI0911764A2 (pt) inibidores cíclicos de 11beta-hidroxiesteroide desigrogenase 1
BRPI0909527A2 (pt) derivados substituídos de 4-aminociclohexano
BRPI1008749A2 (pt) Derivados de benzodiazepina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
BR112013013914A2 (pt) derivados de hidantoína úteis como inibidores de kv3
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0915064A2 (pt) derivados de qunoxalinadiona
ECSP12011999A (es) Derivados benzamida sustituidos
BRPI0914544A2 (pt) derivados de pirimidona substituídos
BRPI0914301A2 (pt) derivados de pirimidin-4-ona substituída
BRPI1013844A2 (pt) derivados de piridina-isoxazol
CR10879A (es) Cyclized derivatives as eg-5 inhibitors
DK2397480T3 (da) Diazepindionderivat
DK2275414T3 (da) Cyclopentylacrylamidderivat
BRPI0920496A2 (pt) derivados substituídos de pirimidina etriazina
BRPI0920506A2 (pt) derivados acrilamida úteis como inibidores da transição de permeabilidade mitocondrial
DK2318378T3 (da) Quinazolin-derivater
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
BRPI0913234A2 (pt) derivados de tiazolilpiperidina

Legal Events

Date Code Title Description
CJ Change in legal form
PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16